MedTrace Logo

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

NCT05665751 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-08-20

No results posted yet for this study

Summary

This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.

Conditions

Interventions

DRUG

TLC-3595 Dose 1

Tablets administered orally

DRUG

TLC-3595 Dose 2

Tablets administered orally

DRUG

Placebo

Tablets administered orally

Sponsors & Collaborators

  • OrsoBio, Inc

    lead INDUSTRY

Principal Investigators

  • OrsoBio Study Director · OrsoBio, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-08
Primary Completion
2024-09-30
Completion
2024-12-31

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05665751 on ClinicalTrials.gov